Amyloid Beta 42/40 Test

If you could look inside your brain right now, would you want to know whether the protein buildup linked to Alzheimer's disease has started? For most people, the answer is yes, especially if it meant you could act early. The Aβ42/40 ratio (amyloid beta 42/40) is a blood test that answers exactly that question. A lower ratio signals that a specific form of amyloid protein is being pulled out of your bloodstream and deposited into plaques in your brain tissue. That process can begin 15 to 20 years before any noticeable memory problems.

Until recently, the only ways to detect brain amyloid were a spinal tap or a specialized brain scan called an amyloid PET, both expensive, invasive, and hard to access. This blood test offers a practical alternative. In validation studies across multiple countries and cohorts, high-precision plasma Aβ42/40 identified brain amyloid with accuracy approaching that of a PET scan, catching changes that no routine blood panel, cognitive screening, or standard brain MRI would reveal.

What This Ratio Actually Measures

Your body constantly produces a protein called amyloid precursor protein, or APP. Enzymes in your brain and other tissues clip APP into smaller pieces called amyloid beta peptides. Two of these fragments matter most: one that is 42 amino acids long (Aβ42) and one that is 40 amino acids long (Aβ40). Both circulate in your blood, but they behave very differently.

Aβ42 is stickier. It clumps together more easily, and it is the primary building block of the amyloid plaques found in the brains of people with Alzheimer's disease. When Aβ42 starts clumping into plaques in your brain, less of it makes it back into your bloodstream, so your plasma level drops. Aβ40, by contrast, does not clump as readily and reflects your overall amyloid production rate. Dividing Aβ42 by Aβ40 corrects for individual differences in how much total amyloid your body makes. What you are left with is a cleaner signal of whether Aβ42 is being trapped in brain plaques.

Research on spinal fluid (a related but different specimen from blood) first established that this ratio is a better diagnostic tool than Aβ42 alone. A spinal-fluid study of over 2,300 participants found that the Aβ42/40 ratio distinguished Alzheimer's dementia from other types of dementia and from healthy aging better than measuring Aβ42 alone. In a separate spinal-fluid cohort of 575 people with mild cognitive impairment (MCI), adding the Aβ42/40 ratio to the standard biomarker profile increased the ability to predict which individuals would go on to develop Alzheimer's dementia. These spinal-fluid findings provided the scientific basis for the plasma version of the test.

Alzheimer's Disease Risk

The link between a low plasma Aβ42/40 ratio and Alzheimer's pathology is one of the most consistently replicated findings in dementia research. In a study of 158 participants, a plasma Aβ42/40 below 0.1218 (measured by high-precision mass spectrometry) identified people who were 15 times more likely to later convert to amyloid PET positive, meaning plaques appeared on brain imaging. That is a striking signal from a simple blood draw.

In community-dwelling older adults tracked over time, those with lower plasma Aβ42/40 showed faster cognitive decline. A French population study of 327 adults over age 65 found that those with lower ratios had roughly 3.5 times the risk of developing dementia within six years, even after adjusting for age, sex, and education. A separate analysis of 2,864 participants in a large US cohort showed that changes in plasma Alzheimer's biomarkers, including Aβ42/40, were associated with incident dementia beginning in midlife and continuing through late life.

Heart and Vascular Connections

Brain amyloid is not the whole story. Research involving 719 participants found that plasma amyloid levels are also associated with vascular disease. Higher plasma Aβ40 (the denominator of the ratio) has been linked to worse cardiac function, white matter lesions in the brain, and conditions like hypertension and diabetes. In a study of over 4,100 adults, higher Aβ40 was associated with an increased risk of new-onset heart failure, particularly among men.

In people who had a heart attack, elevated Aβ40 predicted higher long-term mortality in a cohort of 1,879 patients. These findings suggest that amyloid biology is not confined to the brain. The test you order measures the ratio, and a low ratio specifically points toward brain amyloid deposition, but your doctor may also want to consider the individual Aβ42 and Aβ40 numbers in the context of your cardiovascular health.

Cognitive Impairment in Kidney Disease

People on hemodialysis (a treatment that filters waste from the blood when kidneys fail) face a higher risk of cognitive impairment, and the Aβ42/40 ratio appears relevant here too. In a multicenter study of 311 hemodialysis patients, a lower plasma Aβ42/40 ratio was able to distinguish between normal cognition, mild cognitive impairment, and dementia. Kidney function independently affects plasma amyloid levels because the kidneys help clear these peptides from the blood, so interpreting results in people with impaired kidney function requires extra care.

How Well the Test Performs

Not all Aβ42/40 assays are created equal. A head-to-head comparison of eight different plasma assays found dramatic differences in accuracy. The best-performing method, called immunoprecipitation mass spectrometry (a two-step lab process that first isolates the target proteins from blood, then precisely measures their amounts), achieved the highest agreement with amyloid PET results. Less precise antibody-based platforms performed meaningfully worse. When you order this test, the specific laboratory method matters.

The table below uses a statistic called AUC, or area under the curve. Think of it as an accuracy score on a 0-to-1 scale, where 1.0 means the test is perfect and 0.5 means it is no better than flipping a coin.

The practical takeaway: if your test uses a high-precision mass spectrometry method, its ability to detect brain amyloid approaches that of a PET scan costing thousands of dollars. If it uses a less validated platform, the result carries more uncertainty. Always confirm which assay your lab uses.

Reference Ranges

Because cutpoints depend heavily on the specific assay, there is no single universal "normal" range for plasma Aβ42/40. The numbers below come from published research cohorts and are meant to orient you, not serve as absolute thresholds. Your own lab will likely report results using its own validated cutpoints.

These values come from studies using different assay platforms across populations that are predominantly White and East Asian. They are illustrative, not universal targets.

Notice how the absolute numbers differ by a factor of two or more across platforms. This is exactly why you should compare your results within the same lab and assay over time, not against a cutpoint derived from a different method. In a study of 193 healthy Chinese adults aged 50 to 89, the 95% reference interval for plasma Aβ42/40 (Simoa assay) was 0.022 to 0.064, and the ratio declined with age even in healthy individuals.

Why One Reading Is Not Enough

The good news about this test is that your day-to-day biological variation in plasma Aβ42/40 is low, around 3% over five weeks in memory clinic patients. That means a true change in your ratio is unlikely to be caused by random fluctuation. The reference change value, the minimum shift needed to be confident a real biological change has occurred, is about 15% downward or 17% upward.

Still, a single reading is a snapshot. Brain amyloid accumulates slowly over years to decades. Getting a baseline in your 50s or early 60s and retesting every one to two years gives you a trajectory that is far more informative than any single number. If you are making lifestyle changes aimed at brain health, retesting after 12 to 18 months is reasonable, though keep in mind that changes in this ratio may take years to manifest even when the underlying biology is shifting.

Always retest at the same lab using the same assay. Switching platforms mid-trend will make your comparison meaningless.

When Results Can Be Misleading

Because the difference between a "normal" and "abnormal" plasma Aβ42/40 ratio is small (often only about 10%), even minor confounders can push your result across a threshold.

• Kidney function: Impaired kidneys reduce amyloid clearance from the blood, raising both Aβ42 and Aβ40 and potentially distorting the ratio. A study of nearly 3,000 adults found that lower kidney filtration rate was associated with higher plasma amyloid levels. If your kidney function is reduced, your result may not accurately reflect what is happening in your brain.
• Sample handling: Delays of more than 24 hours before processing the blood sample, or freezing and thawing the sample, can lower both Aβ42 and Aβ40 readings. The ratio is more stable than either peptide alone, but not immune to poor handling. Ask your lab about its processing timeline.
• Medications: Simvastatin (40 mg daily for 12 weeks) raised plasma Aβ42 in a randomized trial of 108 adults with high cholesterol, likely reflecting altered amyloid transport in the blood rather than a brain change. GLP-1 receptor agonists (a class of diabetes and weight-loss drugs like liraglutide) and SGLT-2 inhibitors (like empagliflozin) reduced plasma Aβ40 by 40 to 52% over 12 months in one study of 183 people with type 2 diabetes. These are large peripheral shifts that could substantially affect your result without necessarily reflecting a change in brain amyloid.
• Sleep deprivation: One night of total sleep loss reduced both Aβ40 and Aβ42 in a study of 28 healthy adults, though the ratio was relatively preserved. Get a normal night's sleep before your blood draw to avoid unnecessary noise in your result.

What to Do With Your Result

A low Aβ42/40 ratio does not mean you have Alzheimer's disease right now. It means the protein process that drives Alzheimer's may be underway in your brain. Many people with low ratios remain cognitively normal for years or even decades. But knowing you are amyloid positive fundamentally changes your risk picture.

If your ratio is low, the next step is to add companion blood markers. Phosphorylated tau 217 (p-tau217) is the strongest single blood biomarker for staging Alzheimer's progression, and combining it with Aβ42/40 raises diagnostic accuracy above 90% in multiple studies. GFAP (glial fibrillary acidic protein, a marker of brain inflammation involving support cells called astrocytes) and NfL (neurofilament light chain, a marker of nerve cell damage) add prognostic information about how quickly things might progress. Together, these four markers create a picture that approaches what was previously only possible with a PET scan and spinal tap.

If your ratio is normal, that is reassuring but not a lifetime guarantee. Brain amyloid accumulates gradually. A normal result at 55 does not rule out changes at 65. Periodic retesting, especially if you carry the APOE ε4 gene variant (the strongest common genetic risk factor for Alzheimer's), have a family history of dementia, or notice subtle cognitive changes, is a reasonable strategy.

Consider involving a neurologist or a specialist in cognitive aging if your ratio is low, particularly if companion markers are also abnormal. Anti-amyloid therapies (such as lecanemab) are now available for people with confirmed early Alzheimer's pathology, making early detection more actionable than it has ever been.